Veracyte, Inc.

Valuation Analysis

About the Company

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Veracyte, Inc. Stock at a Glance

Veracyte, Inc. (VCYT) is currently trading at $47.33 with a market capitalization of $3.8B. The trailing P/E ratio stands at 43.82x, with a forward P/E of 24.9x. The 52-week range spans from $22.61 to $50.71; the current price is 6.7% below the yearly high. Year-over-year revenue growth stands at +21.5%. The net profit margin stands at 16.25%.

💰 Dividend

Veracyte, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

10 analysts rate Veracyte, Inc. (VCYT) on consensus: Buy. The average price target is $49.10, implying +3.74% from the current price. Analyst price targets range from $37.00 to $57.00.

Veracyte, Inc.: The Investment Case in Detail

Veracyte, Inc. (VCYT) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 21.5% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 288.9% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 72.91%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

The Bear Case

With a beta near 1.98, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves. Short interest sits at 10.9% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

The EV/EBITDA multiple of 32.4x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

What to Watch Next

• The forward P/E of 24.9x is meaningfully below the trailing 43.82x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to above-average price swings, elevated short interest (10.9%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Veracyte, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.